Richter transformation to Hodgkin lymphoma on Bruton’s tyrosine kinase inhibitor therapy

Leukemia & Lymphoma ◽

10.1080/10428194.2018.1480775 ◽

2018 ◽

Vol 60 (2) ◽

pp. 519-522

Author(s):

Alankrita Taneja ◽

Jade Jones ◽

Stefania Pittaluga ◽

Irina Maric ◽

Mohammed Farooqui ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Hodgkin Lymphoma ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Bruton’S Tyrosine Kinase ◽

Bruton's Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma

Signal Transduction and Targeted Therapy ◽

10.1038/s41392-020-00309-1 ◽

2020 ◽

Vol 5 (1) ◽

Author(s):

Juan Liu ◽

Qianmao Liang ◽

Aoli Wang ◽

Fengming Zou ◽

Ziping Qi ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Hodgkin Lymphoma ◽

Kinase Inhibitor ◽

Bruton’S Tyrosine Kinase ◽

Bruton's Tyrosine Kinase ◽

Non Hodgkin Lymphoma

Download Full-text

Faculty Opinions recommendation of Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1061886.541558 ◽

2007 ◽

Author(s):

Karen Anderson

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Faculty Opinions recommendation of Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1061886.517781 ◽

2007 ◽

Author(s):

Ruth Roberts

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia

American Journal of Hematology ◽

10.1002/ajh.24495 ◽

2016 ◽

Vol 91 (11) ◽

pp. E480-E481 ◽

Author(s):

Simone Claudiani ◽

Jane F. Apperley ◽

Simona Deplano ◽

Jamshid Khorashad ◽

Letizia Foroni ◽

...

Keyword(s):

Chronic Myeloid Leukaemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Myeloid Leukaemia ◽

Cognitive Dysfunction ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Separation of Bruton’s tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography

Journal of Chromatography A ◽

10.1016/j.chroma.2018.12.006 ◽

2019 ◽

Vol 1586 ◽

pp. 106-115 ◽

Author(s):

Shiuhang Henry Yip ◽

Dauh-Rurng Wu ◽

Peng Li ◽

Dawn Sun ◽

Scott H. Watterson ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Supercritical Fluid ◽

Supercritical Fluid Chromatography ◽

Kinase Inhibitor ◽

Bruton’S Tyrosine Kinase ◽

Bruton's Tyrosine Kinase

Download Full-text

Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance

The Lancet Haematology ◽

10.1016/s2352-3026(18)30181-9 ◽

2018 ◽

Vol 5 (12) ◽

pp. e606-e607 ◽

Author(s):

Oliver Ottmann

Keyword(s):

Tyrosine Kinase ◽

Acute Lymphoblastic Leukaemia ◽

Tyrosine Kinase Inhibitor ◽

Lymphoblastic Leukaemia ◽

Kinase Inhibitor ◽

Philadelphia Chromosome ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy ◽

Philadelphia Chromosome Positive

Download Full-text

Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Leukemia ◽

10.1038/leu.2016.231 ◽

2016 ◽

Vol 31 (3) ◽

pp. 585-592 ◽

Author(s):

Z Chen ◽

C Shao ◽

W Wang ◽

Z Zuo ◽

X Mou ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Blast Phase ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability

Molecular Pharmaceutics ◽

10.1021/acs.molpharmaceut.8b00702 ◽

2018 ◽

Vol 15 (11) ◽

pp. 5124-5134 ◽

Author(s):

Stéphanie van Hoppe ◽

Johannes J. M. Rood ◽

Levi Buil ◽

Els Wagenaar ◽

Rolf W. Sparidans ◽

...

Keyword(s):

Cytochrome P450 ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Oral Bioavailability ◽

Kinase Inhibitor ◽

Bruton’S Tyrosine Kinase ◽

Cytochrome P450 3A ◽

Bruton's Tyrosine Kinase ◽

Brain Penetration ◽

Download Full-text

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Blood Cancer Journal ◽

10.1038/bcj.2016.27 ◽

2016 ◽

Vol 6 (5) ◽

pp. e418-e418 ◽

Author(s):

Z Chen ◽

W Wang ◽

J E Cortes ◽

E Liu ◽

R N Miranda ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Chronic Myelogenous Leukemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Myeloid Sarcoma ◽

Myelogenous Leukemia ◽

Prognostic Impact ◽

Blast Phase ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Development of an Efficient Manufacturing Process for Reversible Bruton’s Tyrosine Kinase Inhibitor GDC-0853

Organic Process Research & Development ◽

10.1021/acs.oprd.8b00134 ◽

2018 ◽

Vol 22 (8) ◽

pp. 978-990 ◽

Author(s):

Haiming Zhang ◽

Theresa Cravillion ◽

Ngiap-Kie Lim ◽

Qingping Tian ◽

Danial Beaudry ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Manufacturing Process ◽

Kinase Inhibitor ◽

Bruton’S Tyrosine Kinase ◽

Bruton's Tyrosine Kinase ◽

Efficient Manufacturing

Download Full-text